Video

CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with metastatic castration-resistant prostate cancer (mCRPC) following treatment with abiraterone acetate (Zytiga) plus prednisone.

These events were observed in comparison with patients who were treated with enzalutamide (Xtandi), Behl explains. This study is part of a larger investigation that is seeking to understand the differences between oral therapies used to treat mCRPC, including abiraterone and enzalutamide.

Results showed that patients who were treated with enzalutamide experienced more CNS events and fatigue compared with patients in the abiraterone and prednisone arm, Behl says.

Related Videos
 Philip McCarthy, MD
Lova L. Sun, MD, MSCE
Robert M. Rifkin, MD, FACP
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
Andrew Ip, MD
Anthony B. El-Khoueiry, MD
Daniel King, MD, PhD
Heinz-Josef Lenz, MD, FACP